In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePhysiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.3,4,5-Trichloroaniline nephrotoxicity in vitro: potential role of free radicals and renal biotransformation.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Pharmacogenomics--how close/far are we to practising individualized medicine for children?Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levelsIn vitro study of the variable effects of proton pump inhibitors on voriconazoleTherapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.Predicting the Metabolic Sites by Flavin-Containing Monooxygenase on Drug Molecules Using SVM Classification on Computed Quantum Mechanics and Circular Fingerprints Molecular Descriptors.The role of biotransformation and oxidative stress in 3,5-dichloroaniline (3,5-DCA) induced nephrotoxicity in isolated renal cortical cells from male Fischer 344 rats.Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotypePractice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Quantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Impact of obesity on drug metabolism and elimination in adults and children.Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies.Voriconazole in clinical practice.Drug metabolism for the paediatrician.Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.Voriconazole metabolism is influenced by severe inflammation: a prospective study.An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.Role of Free Radicals and Biotransformation in Trichloronitrobenzene-Induced Nephrotoxicity In Vitro.Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis.Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.The effect of inflammation on voriconazole trough concentrations in children.Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL).Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.Response to: “Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach”A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children
P2860
Q27009221-489DE1B7-BFC2-4EB0-910E-9E93D56C9539Q27312881-1CA8D552-722F-4749-B207-711D8E71BC9CQ34138276-9EF19ECF-6CB2-496E-8337-EACF29E15BE0Q34596313-3E3479D5-7B3E-49FC-A3A1-7550C692F162Q34685545-95444AFC-50DB-459A-B499-BD3A828C98A3Q35105949-24FACBE6-DB42-4FAB-8F37-24174D2F3D0FQ35135951-E5A70420-7169-44F8-9A50-89A412324CE2Q35169112-A5BB3208-23C4-4718-8692-0A458DB91998Q35960842-715056DD-34DB-4CEC-ADD9-05320B4540A8Q35973543-DFFD102F-2D67-4149-8042-ACE06DEB34CEQ36245456-3BAA6050-40AC-4007-A098-82A1B733E99EQ36629157-51B131FC-77BA-4610-970C-14F4F5CBB97AQ36824123-E51A34CA-BE7F-41C7-9466-2C807D150BF8Q36927577-B26D16E1-249D-4A30-9B37-C419CBE340B7Q36969849-7DE8F6D8-E736-414F-9F6D-08616A577470Q37062604-B35597A4-DC17-4925-8CC2-3BD89E81BA0AQ37590883-34E6CBD3-D0C3-4B77-B94F-684084F288C6Q37872786-E066D070-A2F2-45F5-B03E-2EFA9E64ADE9Q37945308-8B02DDB2-C611-4285-84A2-D2429BE56D23Q37997025-3A79E685-82E3-4A63-BA73-BA55E02D3A6DQ38003479-D8928501-BE2E-4BE3-A5E6-B8EFD68BFAAAQ38061736-1FC4CE5A-272E-4591-872B-BE0C8A84AAF4Q38246000-DAC837F7-9918-499F-9F46-EB5D58564F60Q38931118-26216CB0-32D4-4836-AEC6-A77EDC9371BEQ39416464-734613C7-0FAD-4EF0-B2F5-B58DD13C1780Q39466921-B36B8B7A-0DDB-46F6-AB03-C48529AE0E73Q40131074-D1F10E34-8A7F-4C5C-AB6B-8CD0E787093EQ40638888-5AB99F4F-818D-4F43-935B-144A53D0DC6BQ41034308-9177DB72-87C8-46FA-A278-CDBD9EE57341Q41057395-AE2DB2C1-C6EB-4A64-99FF-F092F1427979Q42283754-78BB8CE5-A6FA-4438-AC38-C65AA0ACE1C9Q42321853-BC2162FA-8B4A-4BF4-A4E1-3BBFF1B03A3BQ42720364-6E5E4E7D-832E-4F51-B4D5-42A24E532B67Q47164535-45F5D3A3-9D26-40F7-BC8D-2A97CA9722E3Q47664190-BD5C7773-E6A5-463A-89CF-96188FF5541CQ50534806-907BDBC0-6C65-40EC-B3D1-3CBC014EBD4FQ53171412-2C9F035A-0E6B-4B13-B9CD-B3355BAE4E8FQ57730438-CBC00986-095C-4A48-9EEA-A29638EB1CBEQ57730442-42DF026F-3261-4349-8C36-B110A90D0A25
P2860
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@ast
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@en
In vitro hepatic metabolism ex ...... in-containing monooxygenase 3.
@nl
type
label
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@ast
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@en
In vitro hepatic metabolism ex ...... in-containing monooxygenase 3.
@nl
prefLabel
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@ast
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@en
In vitro hepatic metabolism ex ...... in-containing monooxygenase 3.
@nl
P2093
P2860
P356
P1476
In vitro hepatic metabolism ex ...... vin-containing monooxygenase 3
@en
P2093
Daniel K Benjamin
Dhiren R Thakker
Joseph G Ibrahim
Pieter P Annaert
Souzan B Yanni
P2860
P356
10.1124/DMD.109.029769
P577
2010-01-01T00:00:00Z